Physician profile
Jon S Heist
NPI 1760501373
$6,210.94
in general payments reported to CMS, 2019-2025
30 companies · $564 in 2025
The $564 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $872 · 2021: $1,277 · 2022: $937 · 2023: $1,187 · 2024: $845 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,208.26 | 2021-2025 | |
| Amgen INC. | $833.08 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $806.37 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $520.30 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $508.27 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $286.83 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $276.04 | 2022-2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $214.54 | 2019-2022 | |
| Lilly USA, LLC | $199.93 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $192.80 | 2020-2025 | |
| Allergan, INC. | $130.24 | 2020 | |
| Astellas Pharma US INC | $109.11 | 2019-2023 | Veozah |
| Edwards Lifesciences Corporation | $94.34 | 2019 | |
| Merck Sharp & Dohme LLC | $94.32 | 2019-2022 | |
| Axsome Therapeutics, INC. | $89.82 | 2025 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.16 | 2019-2021 | |
| Boston Scientific Corporation | $75.17 | 2022 | |
| Exact Sciences Corporation | $73.83 | 2023 | Cologuard Collection Kit |
| Stryker Corporation | $71.08 | 2024 | Monterey Al, N/A, Capri Corpectomy Cage System |
| Lundbeck LLC | $60.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.21 | 2021-2022 | |
| Eisai INC. | $50.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.45 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $26.10 | 2022 | |
| Althera Pharmaceuticals LLC | $25.97 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $25.16 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $13.58 | 2020 | |
| Almatica Pharma LLC | $13.38 | 2024 | Loreev Xr, Teriparatide |
| Idorsia Pharmaceuticals US INC | $12.78 | 2023 | Quviviq |
| Evoke Pharma, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Heist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.